Differences
This shows you the differences between two versions of the page.
Next revision | Previous revisionBoth sides next revision | ||
tom_shimabukuro [2022/10/15 15:52] pamela created | tom_shimabukuro [2022/10/15 20:12] (current) liam | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ===== Tom Shimabukuro ===== | + | ====== Tom Shimabukuro ====== |
- | {{ :: | + | |
- | Dr. Tom Shimabukuro is the deputy director of the Immunization Safety Office at the US Centers for Disease Control and Prevention (CDC). The Immunization Safety Office conducts post-licensure safety monitoring of US vaccines. | + | {{ :: |
+ | |||
+ | Dr. **Tom Shimabukuro** is the deputy director of the [[Immunization Safety Office]] at the US [[Centers for Disease Control and Prevention]] (CDC). The Immunization Safety Office conducts post-licensure safety monitoring of US vaccines. | ||
Dr. Shimabukuro has also served as the [[:Vaccine Adverse Event Reporting System]] (VAERS) team lead and acting team lead of the [[:Vaccine Safety Datalink]] (VSD) team in the Immunization Safety Office. Prior to coming to the Immunization Safety Office, Dr. Shimabukuro coordinated pandemic influenza planning for CDC’s Immunization Services Division. | Dr. Shimabukuro has also served as the [[:Vaccine Adverse Event Reporting System]] (VAERS) team lead and acting team lead of the [[:Vaccine Safety Datalink]] (VSD) team in the Immunization Safety Office. Prior to coming to the Immunization Safety Office, Dr. Shimabukuro coordinated pandemic influenza planning for CDC’s Immunization Services Division. | ||
Line 7: | Line 9: | ||
He received his medical degree from [[:New York University]]. He did his internship at [[:Emory University]] and preventive medicine residency at the [[:Johns Hopkins University]]. Dr. Shimabukuro also completed a fellowship as an [[:Epidemic Intelligence Service]] Officer at CDC. He is board certified in public health and general preventive medicine. ((https:// | He received his medical degree from [[:New York University]]. He did his internship at [[:Emory University]] and preventive medicine residency at the [[:Johns Hopkins University]]. Dr. Shimabukuro also completed a fellowship as an [[:Epidemic Intelligence Service]] Officer at CDC. He is board certified in public health and general preventive medicine. ((https:// | ||
+ | ==== Vaccine Safety Study ==== | ||
+ | Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring | ||
+ | |||
+ | {{ :: | ||
+ | Winston E Abara, Julianne Gee, Mark Delorey, Ye Tun, Yi Mu, David K Shay, and [[:Tom Shimabukuro]] | ||
+ | |||
+ | Author information Article notes Copyright and License information Disclaimer | ||
+ | CDC COVID-19 Response Team, Centers for Disease Control and Prevention Atlanta, Georgia United States | ||
+ | Corresponding author: Winston Abara; moc.oohay@araba_notsniW | ||
+ | Alternate author: Julianne Gee; vog.cdc@2gzd; | ||
+ | |||
+ | Abstract | ||
+ | Using meta-analytic methods, we calculated expected rates of 21 potential adverse events of special interest (AESI) that would occur following COVID-19 vaccination within 1-, 7-, and 42-day intervals without causal associations. Based on these expected rates, if 10,000,000 persons are vaccinated, 0.5, 3.7, and 22.5 Guillain-Barre syndrome cases; 0.3, 2.4, and 14.3 myopericarditis cases; and 236.5, 1655.5, and 9932.8 all-cause deaths would occur coincidentally within 1, 7, and 42 days post-vaccination, | ||
==== COVID Vaccine Safety Endorsements ==== | ==== COVID Vaccine Safety Endorsements ==== | ||
News Release 3-Sep-2021 | News Release 3-Sep-2021 | ||
No serious health effects linked to mRNA COVID-19 vaccines | No serious health effects linked to mRNA COVID-19 vaccines | ||
{{ :: | {{ :: | ||
+ | |||
Study of 6.2 million patients by Kaiser Permanente and CDC researchers will continue for 2 years. | Study of 6.2 million patients by Kaiser Permanente and CDC researchers will continue for 2 years. | ||
Peer-Reviewed Publication | Peer-Reviewed Publication | ||
Line 22: | Line 38: | ||
The study reported findings from mid-December 2020 through June 26, 2021. Some of the early findings had been summarized previously and reported at public meetings of the CDC’s Advisory Committee on Immunization Practices, though the JAMA article is the VSD’s first comprehensive report of its safety surveillance of the Pfizer and Moderna mRNA vaccines. | The study reported findings from mid-December 2020 through June 26, 2021. Some of the early findings had been summarized previously and reported at public meetings of the CDC’s Advisory Committee on Immunization Practices, though the JAMA article is the VSD’s first comprehensive report of its safety surveillance of the Pfizer and Moderna mRNA vaccines. | ||
- | Patient medical records were searched electronically | + | “The results of this study are a great example of how seriously CDC takes vaccine safety, |
+ | |||
+ | The VSD’s rapid-cycle analysis for the mRNA COVID-19 vaccines will continue tracking newly vaccinated patients for at least 2 years. The VSD, established in 1990 and led by the CDC, Kaiser Permanente, and other health care systems, is the nation’s premier active surveillance system for vaccine safety. ((https:// | ||
+ | |||
+ | ==== Connection to Twitter PsyOps ==== | ||
- | Vaccine Safety Datalink researchers then applied statistical analysis to determine whether | + | Release |
+ | Over one year on, we still have not seen this data. Is this the FDA's biggest scandal since DES? | ||
+ | {{ :: | ||
+ | Substack - Arkmedic' | ||
- | “The results of this study are a great example of how seriously | + | The CDC rushed out two papers in 2021 to show how safe the COVID vaccines were by reporting on the 5,104 women who had registered for follow-up after their jab. The second |
- | The VSD’s rapid-cycle analysis | + | This means that… |
- | Patient medical records were searched electronically and analysts carried out chart reviews of specific health outcomes | + | The lead author on the original study is Tom Shimabukuro who has almost no image trace on the internet. Tom likes to stay hidden his contacts like to push our favourite Victoria Male into the limelight |
- | Vaccine Safety Datalink researchers then applied statistical analysis to determine whether the number of incidents was above a certain threshold, or “signal.” They concluded that none of the target health outcomes reached the signal, though for some outcomes the findings were less precise because of small numbers | + | Interestingly, |